Amgen, Teijin link for RORy autoimmune candidates
This article was originally published in Scrip
Amgen and the Japanese group Teijin have joined forces to conduct discovery research in a promising avenue for the treatment of autoimmune disorders, the modulation of retinoic acid-related orphan receptor-gamma (RORy).
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.